Clinical Trial Update: Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age [Phase 3]

View source ↗

Summary

A Phase 3 consistency study comparing GSK's MMR vaccine (Priorix) with Merck's M-M-R II in children 12 to 15 months, assessing immunogenicity and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• M-M-R II (Measles, Mumps, and Rubella Vaccine)
• Priorix (Measles-Mumps-Rubella Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rubella, Measles | Phase 3 | Status: COMPLETED | Results posted: 2018-06-28